Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
CRH
CRH
|
+$150M |
| 2 |
Kenvue
KVUE
|
+$98.9M |
| 3 |
Textron
TXT
|
+$50.7M |
| 4 |
Extra Space Storage
EXR
|
+$23.3M |
| 5 |
AngloGold Ashanti
AU
|
+$17.1M |
Top Sells
| 1 |
Apple
AAPL
|
+$1.12B |
| 2 |
Microsoft
MSFT
|
+$890M |
| 3 |
Amazon
AMZN
|
+$463M |
| 4 |
NVIDIA
NVDA
|
+$425M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$316M |
Sector Composition
| 1 | Technology | 29.44% |
| 2 | Healthcare | 13.62% |
| 3 | Consumer Discretionary | 11.97% |
| 4 | Industrials | 9.13% |
| 5 | Communication Services | 8.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1201
Amicus Therapeutics
FOLD
$2.47B
| $5.71M | ﹤0.01% |
469,200
+7,600
| +2% | +$92.4K |
|
1202
Oceaneering
OII
$2.44B
| $5.7M | ﹤0.01% |
221,548
+2,100
| +1% | +$54K |
|
1203
Enovis
ENOV
$1.85B
| $5.68M | ﹤0.01% |
107,800
+1,100
| +1% | +$58K |
|
1204
Associated Banc-Corp
ASB
$4.34B
| $5.68M | ﹤0.01% |
331,740
+3,300
| +1% | +$56.5K |
|
1205
Interparfums
IPAR
$3.44B
| $5.67M | ﹤0.01% |
42,200
+200
| +0.5% | +$26.9K |
|
1206
Piper Sandler
PIPR
$6.1B
| $5.67M | ﹤0.01% |
39,000
+300
| +0.8% | +$43.6K |
|
1207
HUB Group
HUBG
$2.24B
| $5.66M | ﹤0.01% |
144,200
+1,200
| +0.8% | +$47.1K |
|
1208
Rush Enterprises Class A
RUSHA
$4.41B
| $5.66M | ﹤0.01% |
138,550
+400
| +0.3% | +$16.3K |
|
1209
Plexus
PLXS
$3.72B
| $5.65M | ﹤0.01% |
60,800
+500
| +0.8% | +$46.5K |
|
1210
Burford Capital
BUR
$2.85B
| $5.65M | ﹤0.01% |
409,072
+3,869
| +1% | +$53.5K |
|
|
MDC
1211
DELISTED
M.D.C. Holdings, Inc.
MDC
| $5.63M | ﹤0.01% |
136,643
+25,300
| +23% | +$1.04M |
|
1212
Artisan Partners
APAM
$3.29B
| $5.63M | ﹤0.01% |
150,500
+2,600
| +2% | +$97.3K |
|
1213
Premier
PINC
$2.2B
| $5.63M | ﹤0.01% |
261,812
+3,000
| +1% | +$64.5K |
|
1214
Innospec
IOSP
$2.06B
| $5.59M | ﹤0.01% |
54,703
+400
| +0.7% | +$40.9K |
|
|
PDCO
1215
DELISTED
Patterson Companies, Inc.
PDCO
| $5.59M | ﹤0.01% |
188,500
-3,000
| -2% | -$88.9K |
|
1216
Fortrea Holdings
FTRE
$943M
| $5.57M | ﹤0.01% |
+194,820
| New | +$5.57M |
|
1217
Ameris Bancorp
ABCB
$5.12B
| $5.56M | ﹤0.01% |
144,844
+1,400
| +1% | +$53.7K |
|
1218
Ultragenyx Pharmaceutical
RARE
$2.95B
| $5.55M | ﹤0.01% |
155,652
+2,800
| +2% | +$99.8K |
|
1219
J&J Snack Foods
JJSF
$2.03B
| $5.55M | ﹤0.01% |
33,900
+400
| +1% | +$65.5K |
|
1220
Brady Corp
BRC
$3.74B
| $5.54M | ﹤0.01% |
100,900
+500
| +0.5% | +$27.5K |
|
|
RCM
1221
DELISTED
R1 RCM Inc. Common Stock
RCM
| $5.54M | ﹤0.01% |
367,700
+3,500
| +1% | +$52.7K |
|
1222
Intellia Therapeutics
NTLA
$1.22B
| $5.51M | ﹤0.01% |
174,400
+1,900
| +1% | +$60.1K |
|
1223
Frontdoor
FTDR
$4.86B
| $5.5M | ﹤0.01% |
179,703
+2,200
| +1% | +$67.3K |
|
1224
Amkor Technology
AMKR
$6.31B
| $5.49M | ﹤0.01% |
243,000
+2,300
| +1% | +$52K |
|
1225
Frontline
FRO
$5.19B
| $5.46M | ﹤0.01% |
295,670
+4,617
| +2% | +$85.3K |
|